Top Markets
Coin of the day
VISEN Pharmaceuticals VISEN Pharmaceuticals

VISEN Pharmaceuticals

2561
Ранг среди акций #16900
VISEN Pharmaceuticals operates as an investment holding company, concentrating... VISEN Pharmaceuticals operates as an investment holding company, concentrating on the development and commercialization of endocrine treatments across mainland China, Hong Kong, and Taiwan. Their flagship product, Lonapegsomatropin, offers a once-weekly, long-acting growth hormone replacement designed for pediatric growth hormone deficiency. The company is also progressing other therapies, such as TransCon CNP (navepegritide), a long-acting prodrug utilizing c-type natriuretic peptide for achondroplasia, and Palopegteriparatide, a daily parathyroid hormone replacement therapy intended for chronic hypoparathyroidism. VISEN has forged strategic collaborations with Shanghai Pharmaceutical and United Family Healthcare. The enterprise was founded in 2018 and is based in Suzhou, China.
Цена акции
$2.46
Рыночная капитализация
$268.65M
Изменение (1 день)
-1.73%
Изменение (1 год)
-57.06%
Страна
CN
Торговля VISEN Pharmaceuticals (2561)

Категория

Коэффициент P/B для VISEN Pharmaceuticals (2561)
Коэффициент P/B на 2026 TTM: 0
Согласно последним финансовым отчетам и цене акций VISEN Pharmaceuticals, текущий коэффициент P/B (TTM) составляет 0. В конце 2026 он составлял 0.
История P/B для VISEN Pharmaceuticals с 2026 по 2026
Коэффициент P/B в конце каждого года
Год P/B Изменить
Недостаточно данных для указанных дат.
Коэффициент P/B для аналогичных компаний или конкурентов